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The study of pancreatic ductal adenocarcinoma (PDAC), the fourth leading cause of cancer-related deaths in the U.S., is invariably associated with a question: What makes the mortality rate of this tumor almost equal to its incidence rate? 1 A median survival time of 20-22 months in patients affected by early PDAC declines to 9-10 months in patients bearing advanced lesions. 2 This scenario mainly depends on the clinical and biological features of PDAC, which causes symptoms that vary depending on the location of the tumor within the pancreatic gland and on tumor stage. Although the surgical removal of early PDAC lesions can be curative, such tumors are often asymptomatic or poorly symptomatic and hence often fail to be diagnosed. Conversely, advanced forms of PDAC quickly spread to other organs and are refractory to chemotherapy.
From a biological viewpoint, PDAC evolves from a premalignant state to a fully invasive tumor by accumulating genetic and epigenetic mutations that mainly involve the KRAS oncogene and the oncosuppressor genes CDKN2A, TP53 and SMAD4. Although the rapid progression of PDAC stems from cancer cell-intrinsic genetic alterations, it is also the result of complex interactions between malignant and stromal cells. 3 Indeed, cancer cells and stromal inflammatory cells may create a microenvironment that supports rather than counteracts PDAC growth and dissemination to distant organs. In particular, this is achieved by the activation of immunosuppressive networks coupled to the inhibition of immune effector cells in the peripheral blood, secondary lymphoid organs and in the tumor stroma and/or via alterations in the expression of immunomodulatory molecules expressed on the surface of immune cells. As recently demonstrated by us, 4 PDAC is associated with reduced levels of circulating antitumor CD8 + T cells as well as with reduced and increased numbers of dendritic cells (DCs) and myeloid derived immune suppressive cells (MDSCs), respectively, in the blood and spleen. These findings support the notion that the deregulation of both lymphoid and myeloid cells is a hallmark of PDAC. Human MDSCs comprise a set of immature myeloid cells (IMCs) that share the ability to exert immunosuppressive functions in spite of their phenotypic heterogeneity. Conversely, mouse MDSCs are relatively homogenous and always express CD11b and Gr1. 5 We found that different MDSC subsets accumulate in the blood and spleen of PDAC patients, according to different disease stage: (1) A variety of cancer cell-and immune cell-derived soluble proteins may be responsible for the effects of PDACconditioned media on immune cells. We focused on the S100A8/A9 complex because it has been (1) involved in the establishment of a favorable environment for metastases, (2) implicated in the recruitment of MDSCs and the stimulation of their immunosuppressive functions whereas IMCs lacking CTLA4 exerted bona fide immunosuppressive functions. Immune cell alterations detected in PDAC patients may be the consequence of a direct or indirect crosstalk between cancer cells and the immune system, and this may occur within neoplastic lesions as well as at a systemic level. Soluble mediators directly secreted by tumor cells and/or indirectly produced by stromal inflammatory cells surely represent key players in this crosstalk. To get further insights into this issue, we studied the effects of culture media conditioned by PDAC cell lines exhibiting different metastatic potential on immune cells. In agreement with clinical data, well-differentiated and poorly metastatic PDAC BxPC3 cells induced the expansion of PDAC.
6 CTLA4 is believed to participate in the immunosuppressive activity of regulatory T cells (Tregs). PDL1 is expressed by cancer cells as well as by cellular components of the tumor microenvironment and its expression by malignant cells appears to be of prognostic significance in PDAC patients. Furthermore, the blockade of both these molecules with specific antibodies has recently been demonstrated to constitute a promising immunotherapeutic strategy. 7 In PDAC patients, splenic DCs expressed elevated levels of PDL1 while CTLA4 expression by splenic CD33 + CD14 + HLA-DR − monocytic MDSCs was reduced. 4 From a functional perspective, increased PDL1 expression was not associated with immunosuppression, and (3) shown to be intimately link with the deletion of SMAD4. 5, 8 In fact, when SMAD4 is deleted, PDAC cells acquire the ability to express high levels of the S100A8/A9 complex. S100A8/A9 caused an expansion of CD33 + CD14 + HLA-DR − monocytic MDSCs while reducing the levels of CTLA4 on their surface.
As it failed to modulate CD33 + CD14 − HLA-DR − MDSCs, these findings suggest that the S100A8/A9 complex constitutes one of the immunosuppressive soluble mediators released by advanced PDACs. This complex probably operates by binding to the advanced glycosylation end product-specific receptor (AGER, best known as RAGE), 9 which has previously been shown to promote the accumulation of MDSCs in murine models of PDAC. 10 Thus, we suggest that the accumulation of genetic alterations by PDAC cells is paralleled by a progressive imbalance between regulatory and effector immune cells, ultimately resulting in the establishment of immunosuppressive networks that allow for rapid tumor progression (Fig. 1) .
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